Ignite Creation Date:
2024-07-17 @ 11:30 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06472258
Status:
COMPLETED
Last Update Posted:
2024-06-26
First Post:
2024-06-14
Brief Title:
Efficacy of Only IV Artesunate Versus IV Artesunate Plus IV Quinine in the Treatment of Severe Malaria in Children A Comparative Study
Sponsor:
RESnTEC Institute of Research
Organization:
RESnTEC Institute of Research
Study Overview
Official Title:
Efficacy of Only IV Artesunate Versus IV Artesunate Plus IV Quinine in the Treatment of Severe Malaria in Children A Comparative Study
Status:
COMPLETED
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The WHO recommends artesunate as the drug of choice for the treatment of severe malaria However the efficacy of this single drug as compared to the combined drug regimen remained questionable and the clinical response was considered delayed or inappropriate Therefore this research intended to evaluate the efficacy of only IV artesunate versus IV artesunate plus IV quinine in the treatment of severe malaria in children The findings of the study would be helpful knowing whether the two drugs when given together have considerable benefit over single-drug therapy when given for the same
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None